News

US FDA approves gradual dosing for Lilly Alzheimer's drug
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
pharmaphorum3h
FDA clears new, safer regimen for Lilly's Alzheimer's drug
Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...
BioSpace5h
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
Fierce Pharma5h
Eli Lilly's Kisunla wins FDA nod for new dosing with fewer side effects in Alzheimer's
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a ...
PharmiWeb1d
The Scottish Medicines Consortium (SMC) has announced that following a Fast Track Resubmission by Eisai, Leqembi® (lecanemab) has not been recommended for use in the National ...
HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...
Stocktwits on MSN1d
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...
PharmTech1d
Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium
The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.